Palvella Therapeutics’ (PVLA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $38.00 price objective on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2029 earnings at ($0.69) EPS.

Separately, Cantor Fitzgerald initiated coverage on shares of Palvella Therapeutics in a report on Wednesday, December 18th. They set an “overweight” rating for the company.

Palvella Therapeutics Stock Up 10.4 %

PVLA opened at $13.25 on Friday. The firm has a market cap of $17.49 million, a P/E ratio of -1.10 and a beta of 0.61. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32.

Insiders Place Their Bets

In related news, Director George M. Jenkins acquired 4,000 shares of the firm’s stock in a transaction on Wednesday, December 18th. The stock was bought at an average cost of $12.93 per share, with a total value of $51,720.00. Following the acquisition, the director now directly owns 180,671 shares in the company, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 6.39% of the stock is owned by company insiders.